We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sweeping FDA Rule Would Overhaul ANDA and 505(b)(2) Applications Process
Sweeping FDA Rule Would Overhaul ANDA and 505(b)(2) Applications Process
Drugmakers claiming a product is protected by a patent will need to make much more detailed justifications of their claims under a rule proposed by the FDA on Feb. 5.